Nektar Therapeutics
NASDAQ:NKTR · NASDAQ Global Select
-$1.24 today
Vol 0.81M · Avg 1.00M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-182.6%
avg -213.3%
ROIC
-52.8%
avg -24.4%
ROA
-58.5%
avg -31.6%
Analysis
ROIC is currently the strongest return metric at -52.8% versus its period average of -24.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Howard W. Robin | Chief Executive Officer, President & Director | $2.33M | — | 73 | $75,045.00 | 0.38% |
Jonathan Zalevsky | Senior Vice President and Chief Research & Development Officer | $1.19M | — | 51 | $15,437.00 | 0.08% |
Sandra A. Gardiner | Interim Chief Financial Officer | $686,400.00 | — | 60 | $0.00 | <0.01% |
Linda Rubinstein | Chief Financial Officer and Principal Financial & Accounting Officer | $460,850.00 | — | 59 | $0.00 | <0.01% |
Ken Franke | Senior Vice President of Biologics Process Development & Manufacturing | — | — | — | — | — |
Mary Tagliaferri | Chief Medical Officer | — | — | 60 | — | — |
Elizabeth Zhang | VP of Legal, Corporate Counsel & Secretary | — | — | — | — | — |
Jennifer Ruddock | Chief Business Officer | — | — | — | — | — |
Robert Bacci | Chief People Officer and Head of Quality & Facilities | — | — | — | $8,000.00 | 0.04% |
Takahiro Miyazaki | Senior VP & Head of Research | — | — | — | — | — |
Charleen Jue | Senior Vice President of Clinical Development Operations | — | — | — | — | — |
Vivian Wu | Investor Relations | — | — | — | — | — |
Jason Barnard | Chief Accounting Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
29
$1.72M
Net Sentiment
$1.72M
Net selling
Most Active
ROBIN HOWARD W
16 transactions
1–10 of 29
Analysis
Insiders reported 0 buys worth $0.00 and 29 sells worth $1.72M over the last 12 months. That adds up to net selling of $1.72M. ROBIN HOWARD W was the most active insider with 16 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | +41.7% | -1.0% (15yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Recent growth has been strongest in Revenue at +41.7% over three years. Forward estimates point to Revenue at -1.0% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Relay Therapeutics, Inc.
NASDAQ:RLAY
$2.79B
Enliven Therapeutics, Inc.
NASDAQ:ELVN
$2.72B
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.68B
Atai Beckley Inc.
NASDAQ:ATAI
$1.47B
Inhibrx Biosciences, Inc.
NASDAQ:INBX
$1.34B
Immatics N.V.
NASDAQ:IMTX
$1.30B
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLX
$1.28B
Xencor, Inc.
NASDAQ:XNCR
$930.11M
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$880.42M
Sana Biotechnology, Inc.
NASDAQ:SANA
$850.18M
Who manages NKTR?
Nektar Therapeutics (NKTR) lists 13 active executives. The top listed executive is Jonathan Zalevsky, Senior Vice President and Chief Research & Development Officer.
Are NKTR insiders buying or selling?
Recent insider activity shows net buying of $42.11M.
Explore More
Continue the stock analysis
Jump to another research area for this company.